FDA APPROVED
FOR COLON CANCER SCREENING



shield® by GUARDANT

You're invited to an exclusive discussion:

Closing the Colorectal Cancer Screening Adherence Gap with the Shield™ Blood Test

Register

RSVP BY: 10/20/2026



Michelle Pearlman
CEO & Co-founder Prime Institute and ByteMD
Prime Institute and ByteMD

Michelle Pearlman, M.D., is a board-certified gastroenterologist and specialist in internal medicine and obesity medicine. As a nationally recognized expert in digestive health and preventive care, Dr. Pearlman will share the latest insights on evolving landscape of colorectal cancer screening, including clinical data behind the Shield blood test and its potential to increase screening adherence and improve patient outcomes.

Venue:
Flemings Prime Steakhouse
8306 Tourist Center Drive
Bradenton. FL 34201

Date:
Thursday, October 29, 2026

Time:
6:15 PM Eastern Daylight Time

Host:
Natalie Lee
nlee@guardanthealth.com
941-404-0346

Agenda

- Discuss a patient case demonstrating why colorectal cancer (CRC) screening adherence still falls short
- Understand why CRC still remains a major public health challenge despite existing screening options
- Explore Shield blood test performance published in the *New England Journal of Medicine*
- Learn how to identify patients at risk of non-adherence and integrate testing into your workflow

The Shield™ test is an IVD intended for colorectal cancer screening. Please click here for Important Product Information, including precaution and limitations.

Client Services: 1.855.722.7335 • ScreeningSupport@guardanthealth.com • shieldbloodtest.com/hcp

shield® by GUARDANT